# Capricor (CAPR) — News

CAPR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/capr/news

## Recent headlines

- [Capricor Therapeutics shares gain 15.6%](https://www.ainvest.com/news/capricor-therapeutics-shares-gain-15-6-2609) — AInvest Wire, Sep 30, 2026
  Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares rose 15.6% on September 30, 2026, following a recent earnings report and updated guidance. The company reported a loss of $0.70 per share for the last quarter, which was below the estimated loss of $0.59 per share, representing a 18.87% earnings…
- [Capricor Therapeutics, Inc.: B. Riley raises to buy from neutral; raises target price to $21 from $5](https://www.ainvest.com/news/capricor-therapeutics-riley-raises-buy-neutral-raises-target-price-21-5-2609) — AInvest Wire, Sep 14, 2026
  B. Riley & Co. has upgraded its rating for Capricor Therapeutics, Inc. (CAPR) from "neutral" to "buy," reflecting a more favorable outlook on the company's prospects. Alongside the rating change, the firm has raised its price target for the stock to $21 from $5. The adjustment suggests that B.…
- [Capricor Therapeutics shares up 5% after Piper Sandler raises to overweight from neutral](https://www.ainvest.com/news/capricor-therapeutics-shares-5-piper-sandler-raises-overweight-neutral-2609) — AInvest Wire, Sep 1, 2026
- [Capricor Therapeutics spikes higher, up 33%](https://www.ainvest.com/news/capricor-therapeutics-spikes-higher-33-2608) — AInvest Wire, Aug 24, 2026
  Capricor Therapeutics (NASDAQ: CAPR) shares surged 33% on August 24, 2026, following the release of updated clinical trial data for its lead candidate, CAP-1002, in the treatment of Duchenne muscular dystrophy (DMD) [1]. The data, presented at a recent medical conference, showed improved functional…
- [Capricor Therapeutics announces extension of PDUFA target action date as FDA continues review of DeramioCel BLA](https://www.ainvest.com/news/capricor-therapeutics-announces-extension-pdufa-target-action-date-fda-continues-review-deramiocel-bla-2608) — AInvest Wire, Aug 24, 2026
  Capricor Therapeutics (NASDAQ: CAPR) has announced that the U.S. Food and Drug Administration (FDA) has agreed to extend the Prescription Drug User Fee Act (PDUFA) target action date for its Biologics License Application (BLA) for deramiocel, an investigational cell therapy for the treatment of…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).